A randomised, placebo-controlled clinical trial with the α2/3/5 subunit selective GABAA positive allosteric modulator PF-06372865 in patients with chronic low back pain-Reference-Cited by-同舟云学术

A randomised, placebo-controlled clinical trial with the α2/3/5 subunit selective GABAA positive allosteric modulator PF-06372865 in patients with chronic low back pain

Published:2018-05-17 Issue:9 Volume:159 Page:1742-1751
ISSN:0304-3959
Container-title:Pain
language:en
Short-container-title:PAIN

Author:

Gurrell Rachel,Dua Pinky,Feng Gang,Sudworth Maria,Whitlock Mark,Reynolds David S.,Butt Richard P.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Anesthesiology and Pain Medicine,Clinical Neurology,Neurology

Reference52 articles.

1. Epidemiological features of chronic low back pain;Anderson;Lancet,1999

2. Activity of tetrazepam (Myolastan) in low back pain. A double-blind trial v. placebo;Arbus;Clin Trial J,1990

3. GABAA receptor alpha2/alpha3 subtype-selective modulators as potential nonsedating anxiolytics;Atack;Curr Top Behav Neurosci,2010

4. Preclinical and clinical pharmacology of TPA023B, a GABAA receptor α2/α3 subtype-selective partial agonist;Atack;J Psychopharm,2010

5. MRK-409 (MK-0343), a GABAA receptor subtype-selective partial agonist, is a non-sedating anxiolytic in preclinical species but causes sedation in humans;Atack;J Psychopharmacol,2011

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Use of patient-reported global assessment measures in clinical trials of chronic pain treatments: ACTTION systematic review and considerations;Pain;2024-05-14

2. New GABA-Targeting Therapies for the Treatment of Seizures and Epilepsy: II. Treatments in Clinical Development;CNS Drugs;2023-08-21

3. Activation of α6-containing GABAA receptors induces antinociception under physiological and pathological conditions;Pain;2022-08-24

4. Pronounced antiseizure activity of the subtype‐selective GABA _A positive allosteric modulator darigabat in a mouse model of drug‐resistant focal epilepsy;CNS Neuroscience & Therapeutics;2022-08-14

5. The imidazodiazepine, KRM-II-81: An example of a newly emerging generation of GABAkines for neurological and psychiatric disorders;Pharmacology Biochemistry and Behavior;2022-02